Related references
Note: Only part of the references are listed.Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database
Ameenathul Mazaya Fawzy et al.
DIABETES OBESITY & METABOLISM (2023)
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial
Massar Omar et al.
CIRCULATION-HEART FAILURE (2022)
Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure A Systematic Review and Meta-analysis
Xinyu Zou et al.
ANNALS OF INTERNAL MEDICINE (2022)
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
Mikhail N. Kosiborod et al.
CIRCULATION (2022)
Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study
Hiroshi Akasaka et al.
GERIATRICS & GERONTOLOGY INTERNATIONAL (2022)
SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
Alexey Karpushev et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin
Li Ma et al.
THERANOSTICS (2022)
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction A Substudy of the Empire HF Randomized Clinical Trial
Massar Omar et al.
JAMA CARDIOLOGY (2021)
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study
Jonas Oldgren et al.
DIABETES OBESITY & METABOLISM (2021)
Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) Inhibition-Induced Relaxation in Arteries From Human Visceral Adipose Tissue
Alessandro De Stefano et al.
HYPERTENSION (2021)
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
Koenraad Philippaert et al.
CIRCULATION (2021)
SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens
Yu Jin Chung et al.
CARDIOVASCULAR RESEARCH (2021)
Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart
Yu Jin Chung et al.
CARDIOVASCULAR RESEARCH (2021)
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
Matthew M. Y. Lee et al.
CIRCULATION (2021)
Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure
Hidekazu Tanaka et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Kim A. Connelly et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
Jagdeep S. S. Singh et al.
DIABETES CARE (2020)
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
Alexander J. M. Brown et al.
EUROPEAN HEART JOURNAL (2020)
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
Donato Cappetta et al.
PHARMACOLOGICAL RESEARCH (2020)
Empagliflozin inhibits Na+/H+exchanger activity in human atrial cardiomyocytes
Maximilian Trum et al.
ESC HEART FAILURE (2020)
Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
Alex Ali Sayour et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
Nannan Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma et al.
CIRCULATION (2019)
Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
Daisuke Matsutani et al.
CARDIOVASCULAR DIABETOLOGY (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Empagliflozin directly improves diastolic function in human heart failure
Steffen Pabel et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma et al.
DIABETES CARE (2016)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Share Paper
